Table 2. KIR genotypes and HLA ligand combinations in CHIV- and DENV2-infected patients, compared with healthy donors from the same Gabonese population.

	Control		CHIKV+				DENV-2+
	n	%	n	%	p	pn	n	%	p	pn
Inhibitory KIR genotypes
2DL1	54/54	100	63/73	86.1	0.0049	0.0338	52/52	100	ns	ns
2DL2	35/54	64.8	44/73	60.3	ns	ns	30/52	57.7	ns	ns
2DL3	43/54	79.6	48/73	65.7	ns	ns	41/52	78.8	ns	ns
2DL5	39/54	72.2	40/73	54.8	ns	ns	31/52	59.6	ns	ns
3DL1	54/54	100	73/75	97.3	ns	ns	47/50	94.0	ns	ns
3DL2	54/54	100	68/69	98.5	ns	ns	52/52	100	ns	ns
3DL3	54/54	100	69/69	100	ns	ns	52/52	100	ns	ns
Activating KIR genotypes
2DL4	54/54	100	68/73	93.1	ns	ns	51/52	98.0	ns	ns
2DS1	10/54	18.5	11/55	20.0	ns	ns	15/52	28.8	ns	ns
2DS2	31/54	64.8	18/39	46.1	ns	ns	16/41	39.0	ns	ns
2DS3	19/54	79.6	7/36	19.4	0.0237	ns	6/36	16.7	ns	ns
2DS4	54/54	100	70/70	100	ns	ns	48/48	100	ns	ns
2DS5	18/54	33.3	33/56	58.9	0.0081	0.0489	23/52	44.2	ns	ns
3DS1	4/54	7.4	7/66	10.6	ns	ns	6/50	12.0	ns	ns
Inhibitory KIR-HLA associations
C2+ in 2DL1+	32/47	68.1	44/48	91.6	0.0048	0.0238	26/40	65.0	ns	ns
C1+ in 2DL2+	20/31	64.5	21/33	63.4	ns	ns	14/22	63.6	ns	ns
C1+ in 2DL3+	27/38	71.0	18/40	45.0	ns	ns	21/31	67.7	ns	ns
C1+ in 2DL2/2DL3+	32/47	68.1	28/51	54.9	ns	ns	26/40	65.0	ns	ns
Bw4+ in 3DL1+	33/47	70.2	38/55	69.1	ns	ns	22/31	59.5	ns	ns
Inhibitory KIR3DL1+-HLA-Bw4 subtype associations
Bw4-80Ile+	22/47	46.8	38/55	69.1	0.0274	ns	20/37	54.0	ns	ns
Bw4-80Trn+	12/47	25.5	1/55	1.8	0.0005	0.0011	3/37	8.1	0.0472	ns
Activating KIR-HLA associations
C2+ in 2DS1+	7/8	87.5	8/8	100	ns	ns	9/12	75.0	ns	ns
C1+ in 2DS2+	18/22	64.3	12/17	70.6	ns	ns	10/12	83.3	ns	ns

P: Fisher exact test; Pⁿ: The P values of statistically significant differences were then corrected by the formula Pⁿ = 1−(1−P)ⁿ, where n is the number of comparisons [17].